Preventing the inflammatory response to open-heart surgery: The role of aprotinin and other protease inhibitors

International Journal of Cardiology

Volumn 53, Issue SUPPL., 1996, Pages

  Royston, David ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Anti inflammatory; Aprotinin; Blood sparing agent; Cytoprotectors; Serine protease inhibition

Indexed keywords

AMINOCAPROIC ACID; ANTIINFLAMMATORY AGENT; APROTININ; GABEXATE MESILATE; HEPARIN; NAFAMSTAT; NAFAMSTAT MESILATE; SERINE PROTEINASE INHIBITOR;

BLEEDING; CARDIOPULMONARY BYPASS; HUMAN; INFLAMMATION; OPEN HEART SURGERY; PRIORITY JOURNAL; REVIEW;

EID: 0029896491     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-5273(96)02572-7     Document Type: Article

References (137)

1. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-1291.
2. Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. Trends Pharmacol Sci 1993; 14: 366-376.
3. Laskowski M, Kato I. Protein inhibitors of proteinases. Ann Rev Biochem 1980; 49: 593-626.
4. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983; 33: 479-494.
5. Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995; 49: 954-983.
6. Royston D. High-dose aprotinin therapy: a review of the first five years experience. J Cardiothorac Vasc Anesth 1992; 6: 76-100.
7. Murase M, Usui A, Tomita Y, Maeda M, Koyama T, Abe T. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 1993; 88: 432-436.
8. Minami K, Notohamiprodjo G, Buschler H, Prohaska W, Reichelt W, Korfer R. Alpha-2 plasmin inhibitor-plasmin complex and postoperative blood loss: double-blind study with aprotinin in reoperation for myocardial revascularization (letter). J Thorac Cardiovasc Surg 1993; 106: 934-936.
9. Cosgrove DM, Heric B, Lytle BW et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992; 54: 1031-1036.
10. Lemmer JH Jr., Stanford W. Bonney SL et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. A multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107: 543-451.
11. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55: 971-976.
12. Deviri E, Izhar U, Drenger B, Glick Y, Borman JB. Aprotinin treatment during open heart operation in a patient with severe thrombocytopenia (letter). Ann Thorac Surg 1992; 54: 1018-1019.
13. Akhtar TM, Goodchild CS, Boylan MK. Reversal of streptokinase-induced bleeding with aprotinin for emergency cardiac surgery. Anaesthesia 1992; 47: 226-228.
14. Efstratiadis T, Munsch C, Crossman D, Taylor K. Aprotinin used in emergency coronary operation after streptokinase treatment (see comments). Ann Thorac Surg 1991; 52: 1320-1321.
15. Havel M, Owen AN, Simon P et al. Decreasing use of donated blood and reduction of bleeding after orthotopic heart transplantation by use of aprotinin. J Heart Lung Transplant 1992; 11: 348-349.
16. Kesten S, de Hoyas A, Chaparro C, Westney G, Winton T, Maurer JR. Aprotinin reduces blood loss in lung transplant recipients. Ann Thorac Surg 1995; 59: 877-879.
17. Peterson KL, DeCampli WM, Feeley TW, Starnes VA. Blood loss and transfusion requirements in cystic fibrosis patients undergoing heart-lung or lung transplantation. J Cardiothorac Vasc Anesth 1995; 9: 59-62.
18. Propst JW, Siegel LC, Feeley TW. Effect of aprotinin on transfusion requirements during repeat sternotomy for cardiac transplantation surgery. Transplant Proc 1994; 26: 3719-3721.
19. Royston D. Aprotinin therapy in heart and heart-lung transplantation. J Heart Lung Transplant 1993; 12: S19-25.
20. Brunet F, Mira JP, Belghith M et al. Effects of aprotinin on hemorrhagic complications in ARDS patients during prolonged extracorporeal CO2 removal. Intens Care Med 1992; 18: 364-367.
21. Goldstein D, Selmonridge J, Chen J et al. Use of aprotinin in LVAD recipients reduces blood loss, blood use and perioperative mortality. Ann Thorac Surg 1995; 59: 1063-1068.
22. Vedrinne C, Girard C, Iegaden O et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vasc Anesth 1992; 6: 319-323.
23. Shinfeld A, Zippel D, Lavee I et al. Aprotinin improves hemostasis after cardiopulmonary bypass better than single-donor platelet concentrate. Ann Thorac Surg 1995; 59: 872-876.
24. Rocha E, Hidalgo F, Llorens R, Melero JM, Arroyo JL, Paramo JA. Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 1994; 90: 921-927.
25. Blauhut B, Harringer W, Bettelheim P, Doran JE, Spath P, Lundsgaard Hansen P. Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1994; 108: 1083-1091.
26. de-Bono DP, Pringle S, Underwood I. Differential effects of aprotinin and tranexamic acid on cerebral bleeding and cutaneous bleeding time during rt-PA infusion. Thromb Res 1991; 61: 159-163.
27. Speekenbrink RG, Vonk AB, Wildevuur CR, Eijsman L. Haemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 1995; 59: 438-442.
28. Fuhrer G, Gallimore MI, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass - Effects on the Hageman factor (FXII)-Kallikrein system and blood loss. Blood Coagul Fibrinolys 1992; 3: 99-104.
29. Heller W, Fuhrer G, Gallimore MJ, Michel J, Hoffmeister HE. Changes in the kallikrein-kinin-system after different dose regimen of aprotinin during cardiopulmonary bypass operation. Adv Exp Med Biol 1989; 247b: 43-48.
30. Wachtfogel YT, Kucich U, Hack CE et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-9.
31. Homeister JW, Satoh P, Lucchesi BR. Effects of complement activation in the isolated heart. Role of the terminal complement components. Circ Res 1992; 71: 303-319.
32. Miyamoto Y, Hirose H, Matsuda H et al. Analysis of complement activation profile during cardiopulmonary bypass and its inhibition by FUT-175. Trans Am Soc Artif Intern Organs 1985; 31: 508-511.
33. Dietze G, Wicklymayr M, Mayer L. Evidence for a participation of the kallikrein-kinin system in the regulation of muscle metabolism during hypoxia. Hoppe Seylers Z Physiol Chem 1977; 358: 633-638.
34. Wendt P, Ketterl R, Haas S et al. [Postoperative increase in lactate in total hip endoprosthesis operations. Effect of aprotinin. Results of a clinical double-blind study]. Med Welt 1982; 33: 475-479.
35. Horl M, Sperling M, Herzog I, Muller Esterl W, Horl WH. Effect of aprotinin on metabolic changes in blood following aortofemoral bypass operation. Eur Surg Res 1985; 17: 186-196.
36. Urabe Y, Ideishi M, Sasaguri M, Ikeda M, Arakawa K. Beneficial effects of a serine protease inhibitor in peripheral vascular disease. Am J Cardiol 1993; 72: 218-222.
37. Digiesi V, Bartoli V, Dorigo B. Effect of a proteinase inhibitor on intermittent claudication or on pain at rest in patients with peripheral arterial disease. Pain 1975; 1: 385-389.
38. Welbourn CR, Goldman G, Paterson IS, Valeri CR, Shepro D, Hechtman HB. Neutrophil elastase and oxygen radicals: synergism in lung injury after hindlimb ischemia. Am J Physiol 1991; 260: H1852-1856.
39. Aoki M, Jonas RA, Nomura F et al. Effects of aprotinin on acute recovery of cerebral metabolism in piglets after hypothermic circulatory arrest. Ann Thorac Surg 1994; 58: 146-153.
40. Muylle L, Joos M, Wouters E, De Bock R, Peetermans ME. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions (see comments). Transfusion 1993; 33: 195-199.
41. Muylle L, Peetermans ME. Effect of prestorage leukocyte removal on the cytokine levels in stored platelet concentrates. Vox Sang 1994; 66: 14-17.
42. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994; 34: 20-25.
43. Blajchman MA. An overview of the mechanism of action of antithrombin and its inherited deficiency states. Blood Coagul Fibrinolys 1994; 5(Suppl 1): 55-21; discussion S59-64.
44. Jeske W, Fareed J. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues. Semin Thromb Hemost 1993; 1: 241-247.
45. Bregengaard C, Nordfang O, Ostergaard P et al. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits. Thromb Haemost 1993; 70: 454-457.
46. Bregengard C, Nordfang O, Wildgoose P, Svendsen O, Hedner U, Diness V. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits. Blood Coagul Fibrinolys 1993; 4: 699-706.
47. Hamamoto T, Yamamoto M, Nordfang O, Petersen JG, Foster DC, Kisiel W, Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces. J Biol Chem 1993; 268: 8704-8710.
48. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 1985; 15: 164-168.
49. Koshiyama Y, Ozeki M, Motoyoshi A, Fujita M, Iwaki M, Aoyama T. (Pharmacological studies of FUT-175, nafamostat mesilate. IV. Effects on coagulation, platelets and fibrinolysis). Nippon Yakurigaku Zasshi 1984; 84: 417-428.
50. Nishijima J, Hiraoka N, Murata A et al. Protease inhibitors (gebexate mesylate and ulinastatin) stimulate intracellular chemiluminescence in human neutrophils. J Leukoc Biol 1992; 52: 262-268.
51. Ohno H, Kosaki G, Kambayashi J, Imaoka S, Hirata F. FOY: (ethyl P-(6-guanidinohexanoyloxy) benzoate) methanesulfonate as a serine proteinase inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 1980; 19: 579-588.
52. Redl H, Schlag G, Paul E, Schiesser A. Cellular (thrombocytes, granulocytes) effects of proteinase inhibitors, gabexylate, gabexate mesilate (FOY) and aprotinin. Resuscitation 1986; 14: 81-90.
53. Royston D, The serine antiprotease aprotinin (Trasylol™): a novel approach to reducing postoperative bleeding. Blood Coagul Fibrinolys 1990; 1: 55-69.
54. Tanaka K, Kondo C, Takagi K et al. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery. Asaio J 1993; 39: M545-49.
55. Taenaka N, Shimada Y, Hirata T, Nishijima M, Yoshiya I. New approach to regional anticoagulation in hemodialysis using gabexate mesilate (FOY). Crit Care Med 1982; 10: 773-775.
56. Chabbat J, Porte P, Tellier M, Steinbuch M. Aprotinin is a competitive inhibitor of the factor VIIa-tissue factor complex. Thromb Res 1993; 71: 205-215.
57. Chabbat J, Porte P, Tellier M, Steinbuch M. Study of different human and animal thromboplastins with human factor VIIa in the presence of aprotinin. Thromb Res 1994; 75: 213-218.
58. Uchiba M, Okajima K, Abe H, Okabe H, Takatsuki K. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. Thromb Res 1994; 74: 155-161.
59. Dietrich W, Spannagl M, Jochum M et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization (see comments). Anesthesiology 1990; 73: 1119-1126.
60. Dietrich W, Mossinger H, Spannagl M et al. Haemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations (see comments). J Thorac Cardiovasc Surg 1993; 105: 712-720.
61. Whitten C, Latson T, Allison P et al. Does aprotinin inhibit cardiopulmonary bypass induced inflammation? Anesthesiology 1992; 77: A266.
62. Matsuda Y, Kawata S, Nagase T et al. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Effects of serine protease inhibitor. Cancer 1994; 73: 53-57.
63. Hunyadi J, Kenderessy A, Duda E, Braquet P, Dobozy A. Platelet-activating factor antagonists (BN5202 1 and BN 50730) inhibit tumor necrosis factor-alpha mediated cytotoxicity on murine L929 tumor cells. Mol Immunol 1993; 6: 517-519.
64. Bazil V, Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. J Immunol 1994; 152: 1314-13422.
65. Fleming J, Royston D, Desai J, Westaby S, Taylor K. Neutrophil malondialdehyde content as an indicator of activation during cardiopulmonary bypass. Life Support Sys 1986; 4: 255-261.
66. Liu B, Belboul A, Al-Khaja N et al. Effect of high-dose aprotinin on blood cell filterability in association with cardiopulmonary bypass. Cor Artery Dis 1992; 3: 129-132.
67. Hallett MB, Shandall A, Young HL. Mechanism of protection against "reperfusion injury" by aprotinin. Roles of polymorphonuclear leucocytes and oxygen radicals. Biochem Pharmacol 1985; 34: 1757-1761.
68. Basci A, Shah SV. Trypsin- and chymotrypsin-induced chemiluminescence by isolated rat glomeruli. Am J Physiol 1987; 252: C611-617.
69. 2) and hydroxyl radical production by human polymorphonuclear leukocytes. Hepatogastroenterology 1992; 39: 59-61.
70. Royston D, Fleming J, Desai J et al. Increased peroxide product generation associated with open heart surgery; evidence for free radical generation. J Thorac Cardiovasc Surg 1986; 91: 759-766.
71. Royston D, Bidstrup B, Fleming J, Taylor K. Platelet preservation reduces production of lipid peroxidation products during cardiopulmonary bypass in humans. Am Rev Respir Dis 1987; 135: A135.
72. van-Oeveren W, Jansen NJ, Bidstrup BP et al. Effects of aprotinin on haemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987 44: 640-645.
73. Marx G, Pokar H, Reuter H, Doering V, Tilsner V. The effects of aprotinin on haemostatic function during cardiac surgery. J Cardiothorac Vasc Anesth 1991; 5: 467-474.
74. Mikawa K, Akamatsu H, Maekawa N, Nishina K, Obara H, Niwa Y. Acceleration of phagocytosis in human neutrophils incubated with gabexate mesilate. J Int Med Res 1994; 22: 292-295.
75. Lord RA, Roath OS, Thompson JF, Chant AD, Francis JL. Effect of aprotinin on neutrophil function after major vascular surgery. Br J Surg 1992; 79: 517-521.
76. Gluszko P, Rucinski B, Musial J et al. Fibrinogen receptors in platelet adhesion to surfaces of extracorporeal circuit. Am J Physiol 1987; 252: H615-621.
77. Musial J, Niewiarowski S, Hershock D, Morinelli TA, Colman RW, Edmunds LH Jr. Loss of fibrinogen receptors from the platelet surface during simulated extracorporeal circulation. J Lab Clin Med 1985; 105: 514-522.
78. Harker LA, Malpass TW, Branson HE, Hessel E2, Slichter SJ. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980; 56: 824-834.
79. Zilla P, Fasol R, Groscurth P, Klepetko W, Reichenspumer H, Wolner E. Blood platelets in cardiopulmonary bypass operations. Recovery occurs after initial stimulation, rather than continual activation (see comments). J Thorac Cardiovasc Surg 1989; 97: 379-388.
80. Roath OS, Majer RV, Smith AG. The use of aprotinin in thrombocytopenic patients: a preliminary evaluation. Blood Coagul Fibrinolys 1990; 1: 235-237.
81. Whitten CW, Allison PM, Latson TW, Bossard RF, Rosenberg JA, Ring WS. Management of the thrombocytopenic cardiac surgical patient - A role for aprotinin? Anesth Analg 1994; 79: 796-800.
82. Fricke W, Alling D, Kimball J, Griffith P, Klein H. Lack of efficacy of tranexamic acid in thrombocytopenic bleeding (see comments). Transfusion 1991; 31: 345-348.
83. Harke H, Gennrich M. (Aprotinin-ACD-blood: I. Experimental studies on the effect of aprotinin on the plasmatic and thrombocytic coagulation (author's transi.)). Anaesthesist 1980; 29: 266-276.
84. Ketterl R, Haas S, Lechner F, Kienzle H, Blumel G. (Effect of aprotinin on thrombocytic function during total endoprosthesis surgery of the hip). Med Welt 1980; 31: 1239-1243.
85. Royston BD, Royston D, Pearson JD. Aprotinin inhibits platelet adhesion to endothelial cells. Blood Coagul Fibrinolys 1992; 3: 737-742.
86. Royston BD, Royston D, Coade SB, Morgan DM, Pearson JD. Aprotinin does not inhibit the release of PGI2 or vWF from cultured human endothelial cells. Thromb Haemost 1992; 67: 172-175.
87. Wildevuur CR, Eijsman L, Roozendaal KJ, Harder MP, Chang M, van Oeveren W. Platelet preservation during cardiopulmonary bypass with aprotinin. Eur J Cardiothorac Surg 1989; 3: 533-537.
88. Lu H, Soria C, Soria J et al. Reversible translocation of glycoprotein Ib in plasmin-treated platelets: consequences for platelet function. Eur J Clin Invest 1993; 23: 785-793.
89. Orchard MA, Goodchild CS, Prentice CR et al. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85: 533-541.
90. Soslau G, Horrow J, Brodsky I. Effect of tranexamic acid on platelet ADP during extracorporeal circulation. Am J Hematol 1991; 38: 113-119.
91. Andersson TL, Solem JO, Tengborn L, Vinge E. Effects of desmopressin acetate on platelet aggregation, von Willebrand factor, and blood loss after cardiac surgery with extracorporeal circulation. Circulation 1990; 81: 872-878.
92. Lu H, Soria C, Commin PL et al. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-637.
93. Lavee J, Savion N, Smolinsky A, Goor D, Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass: Electron microscopy study. Ann Thorac Surg 1992; 53: 477-481.
94. Lazenby WD, Russo I, Zadeh BJ et al. Treatment with desmopressin acetate in routine coronary artery bypass surgery to improve postoperative hemostasis. Circulation 1990; 82: 1413-1419.
95. Freise J, Magerstedt P, Schmid K. Inhibition of phospholipase A2 by gabexate mesilate, camostate and aprotinine. Enzyme 1983; 30: 209-212.
96. Freise J, Wittenberg H, Magerstedt P. In vitro inhibition of phospholipase A2 by gabexate mesilate, camostate, and aprotinine. Klin Wochenschr 1989; 67: 149-152.
97. Blauhut B, Gross C, Necek S, Doran J, Spath P, Lundsgaard-Anderson P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958-967.
98. Nagaoka H, Innami R, Murayama F et al. Effects of aprotinin on prostaglandin metabolism and platelet functions in open heart surgery. J Cardiovasc Surg 1991; 32: 31-37.
99. Nagaoka H, Innami R, Funakoshi N, Fujiwara A, Itoh J. (Arachidonic acid metabolism and effectiveness of aprotinin treatment during cardiopulmonary bypass). Nippon Kyobu Geka Gakkai Zasshi 1991; 39: 1723-1730.
100. Tsementzis SA, Hitchcock ER, Meyer CH. Benefits and risks of antifibrinolytic therapy in the management of ruptured intracranial aneurysms. A double-blind placebo-controlled study. Acta Neurochir Wien 1990; 102: 1-10.
101. Tsementzis SA, Meyer CH, Hitchcock ER. Cerebral blood flow in patients with a subarachnoid haemorthage during treatment with tranexamic acid. Neurochirurgia Stuttg 1992; 35: 74-78.
102. Yanamoto H, Kikuchi H, Okamoto S, Nozaki K. Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral vasospasm in rabbits. Neurosurgery 1992; 30: 351-356.
103. Yanamoto H, Kikuchi H, Sato M, Shimizu Y, Yoneda S, Okamoto S. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery 1992; 30: 358-363.
104. Unterberg A, Dautermann C, Baethmann A, Muller Esterl W. The kallikrein-kinin system as mediator in vasogenic brain edema. Part 3: Inhibition of the kallikrein-kinin system in traumatic brain swelling. J Neurosurg 1986; 64: 269-276.
105. Anon. Protease inhibitors for delayed cerebral ischemia after subarachnoid haemorrhage? (editorial). Lancet 1992; 339: 1199-1200.
106. Guidetti B, Spallone A. The role of antifibrinolytic therapy in the preoperative management of recently ruptured intracranial aneurysms. Surg Neurol 1981; 15: 239-248.
107. Kamiya T, Katayama Y, Kashiwagi F, Terashi A. The role of bradykinin in mediating ischaemic brain edema in rats. Stroke 1993; 24: 571-576.
108. Lytle BW, Loop FD, Cosgrove DM et al. Fifteen hundred coronary reoperations. Results and determinants of early and late survival. J Thorac Cardiovasc Surg 1987; 93: 847-859.
109. Jones EL, Weintraub WS, Craver JM, Guyton RA, Cohen CL. Coronary bypass surgery: is the operation different today? J Thorac Cardiovasc Surg 1991; 101: 108-115.
110. Gurevitch J, Paz Y, Barak J et al. Role of protease inhibition in myocardial preservation following ischemia and reperfusion. J Cardiovasc Surg Torino 1994; 35: 95-98.
111. Sunamori M, Innami R, Amano J, Suzuki A, Harrison CE. Role of protease inhibition in myocardial preservation in prolonged hypothermic cardioplegia followed by reperfusion. Effect of aprotinin in an experimental model. J Thorac Cardiovasc Surg 1988; 96: 314-320.
112. Sunamori M, Innami R, Fujiwara H, Yokoyama M, Suzuki A. Significant role of protease inhibition by aprotinin in myocardial protection from prolonged cardioplegia with hypothermia. Adv Exp Med Biol 1988; 24O:399-404.
113. Diaz PE, Fishbein MC, Davis MA, Askenazi J, Maroko PR. Effect of the kallikrein inhibitor aprotinin on myocardial ischemic injury after coronary occlusion in the dog. Am J Cardiol 1977; 40: 541-549.
114. Sunamori M, Sultan I, Suzuki A. Effect of aprotinin to improve myocardial viability in myocardial preservation followed by reperfusion. Ann Thorac Surg 1991; 52: 971-978.
115. Cecena-Seldner F, Villareal B. Effect of kallikrein inhibitor aprotinin on myocardial ischaemia and necrosis in man. Angiology 1980; 31: 488-496.
116. Trofimov GA, Ardashev VN, Serova LS et al. (Heart rupture in the acute period of myocardial infarction: prognostication and ways of prevention). Klin Med Mosk 1994; 72: 22-25.
117. Okamura T, Amano J, Nukariya M et al. (Clinical results of intra-aortic balloon pumping in 51 patients following cardiac surgery). Nippon Kyobu Geka Gakkai Zasshi 1985; 33: 291-297.
118. Sunamori M, Suzuki A. Improved efficacy of intraaortic balloon pumping by pharmacological myocardial protection for postoperative pump failure after coronary revascularization. Jpn J Surg 1988; 18: 61-67.
119. Wendel HP, Heller W, Michel J et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 1995; 109: 1164-1172.
120. Scherberich JE, Mondorf W. Effect of a proteinase inhibitor, aprotinin, on brush border membrane associated arninopeptidase of human kidney cortex. Arzneimittelforschung 1980; 30: 487-491.
121. Rustom R, Grime JS, Maltby P, Stockdale HR, Critchley M, Bone JM. Observations on the early renal uptake and later tubular metabolism of radiolabelled aprotinin (Trasylol) in man: theoretical and practical considerations. Clin Sci Colch 1993; 84: 231-235.
122. Briggs JP, Marin Grez M, Steipe B, Schubert G, Schnermann J. Inactivation of atrial natriuretic substance by kallikrein. Am J Physiol 1984: 247: F480-484.
123. Beierwaltes WH, Prada J, Carretero OA. Effect of glandular kallikrein on renin release in isolated rat glomeruli. Hypertension 1985; 7: 27-31.
124. Sealey JE, Overlack A, Laragh JH, Stumpe KO, Atlas SA. Effect of captopril and aprotinin on inactive renin. J Clin Endocrinol Metab 1981; 53: 626-630.
125. Overlack A, Stumpe KO, Kuhnert M et al. Evidence for participation of kinins in the antihypertensive effect of converting enzyme inhibition. Klin Wochenschr 1981; 59: 69-74.
126. Vemulapalli S, Chiu PJ. Effect of aprotinin-induced kallikrein inhibition on the cardiovascular and renal action of captopril in diuretic-treated dogs. Arch Int Pharmacodyn Ther 1983; 262: 109-123.
127. MacGilchrist A, Craig KJ, Hayes PC, Cumming AD. Effect of the serine protease inhibitor, aprotinin, on systemic haemodynamics and renal function in patients with hepatic cirrhosis and ascites. Clin Sci Colch 1994; 87: 329-335.
128. Johnston PA, Bernard DB, Perrin NS, Levinsky NG. Prostaglandins mediate the vasodilatory effect of mannitol in the hypoperfused rat kidney. J Clin Invest 1981; 68: 127-133.
129. Seto S, Kher V, Scicli AG, Beierwaltes WH, Carretero OA. The effect of aprotinin (a serine protease inhibitor) on renal function and renin release. Hypertension 1983; 5: 893-899.
130. Madeddu P, Oppes M, Soro A et al. The effects of aprotinin, a kallikrein inhibitor, on renin release and urinary sodium excretion in mild essential hypertensives. J Hypertens 1987; 5: 581-586.
131. Kramer HJ, Klingmuller D, Glanzer K, Dusing R. Interaction of the kinin and prostaglandin systems in mediating renal function and intrarenal hemodynamics. Adv Exp Med Biol 1983; 156: 961-968.
132. Muto S, Imai M, Asano Y. Mechanisms of the hyperkalaemia caused by nafamostat mesilate: effects of its two metabolites on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br J Pharmacol 1994; 111: 173-178.
133. Sundt T, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TN, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993; 55: 1418-1424.
134. Dietrich W, Barankay A, Hahnel C, Richter JA. High-dose aprotinin in cardiac surgery: three years experience in 1784 patients. J Cardiothorac Vasc Anesth 1992; 6: 324-327.
135. Paroli A, Antona C, Gerometta P et al. The effect of high dose aprotinin and other factors on bleeding and revisions for bleeding in adult coronary and valve operations: an analysis of 2190 patients during a five-year period (1987-1991). Eur J Cardiothorac Surg 1995; 9: 77-82.
136. Lemmer JH Jr, Stanford W, Bonney SL et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 1995; 59: 132-136.
137. Ranucci M, Corno A, Pavesi M et al. Renal effects of low dose aprotinin in pediatric cardiac surgery. Minerva Anestesiol 1994; 60: 361-366.